Krishan Thirunavukkarasu

549 total citations · 1 hit paper
9 papers, 430 citations indexed

About

Krishan Thirunavukkarasu is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Krishan Thirunavukkarasu has authored 9 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Rheumatology, 5 papers in Genetics and 5 papers in Hematology. Recurrent topics in Krishan Thirunavukkarasu's work include Rheumatoid Arthritis Research and Therapies (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Krishan Thirunavukkarasu is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Autoimmune and Inflammatory Disorders Research (5 papers). Krishan Thirunavukkarasu collaborates with scholars based in Australia, United States and Japan. Krishan Thirunavukkarasu's co-authors include Peter Nash, Kenneth Kwok, Jeffrey R. Curtis, Jamie Geier, Eun Bong Lee, Richard J. Riese, Yoshiya Tanaka, Xavier Mariette, Kevin Winthrop and Lisy Wang and has published in prestigious journals such as Annals of the Rheumatic Diseases, Clinical Therapeutics and Journal of the European Academy of Dermatology and Venereology.

In The Last Decade

Krishan Thirunavukkarasu

9 papers receiving 415 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

2017 302 citations Stanley Cohen, Yoshiya Tanaka et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Krishan Thirunavukkarasu

Since Specialization

Citations

This map shows the geographic impact of Krishan Thirunavukkarasu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krishan Thirunavukkarasu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krishan Thirunavukkarasu more than expected).

Fields of papers citing papers by Krishan Thirunavukkarasu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krishan Thirunavukkarasu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krishan Thirunavukkarasu. The network helps show where Krishan Thirunavukkarasu may publish in the future.

Co-authorship network of co-authors of Krishan Thirunavukkarasu

This figure shows the co-authorship network connecting the top 25 collaborators of Krishan Thirunavukkarasu. A scholar is included among the top collaborators of Krishan Thirunavukkarasu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krishan Thirunavukkarasu. Krishan Thirunavukkarasu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

#	Work	Indexed citations
1	Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib 2019 ·RMD Open ·Paul Bird, Stephen Hall, Peter Nash, Carol A. Connell, Kenneth Kwok, (unknown), Krishan Thirunavukkarasu	42
2	Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs 2018 ·JCR Journal of Clinical Rheumatology ·Paul Bird, W. Bensen, Bassel Elzorkany, Jeffrey Kaine, Bernadette Heizel M. Reyes, (unknown), (unknown), Koshika Soma, Richard Zhang, Krishan Thirunavukkarasu	14
3	Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population 2018 ·Rheumatology and Therapy ·Stephen Hall, Peter Nash, Maureen Rischmueller, David Bossingham, Paul Bird, Nicola Cook, (unknown), Koshika Soma, Kenneth Kwok, Krishan Thirunavukkarasu	8
4	Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials breakdown → 2017 ·Annals of the Rheumatic Diseases ·Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Eun Bong Lee, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Krishan Thirunavukkarasu, Ryan DeMasi, Jamie Geier, Kenneth Kwok, Lisy Wang, Richard J. Riese, J. Wollenhaupt	302
5	Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice 2015 ·Journal of the European Academy of Dermatology and Venereology ·Lynda Spelman, John Su, Pablo Fernández‐Peñas, George A. Varigos, Alan Cooper, Christopher Baker, Min Young Lee, Johannes Ring, Krishan Thirunavukkarasu	23
6	OP0154 Integrated Safety Analysis of Tofacitinib in RA Clinical Trials with A Cumulative Exposure of 12,664 Patient-Years 2014 ·Annals of the Rheumatic Diseases ·Stanley Cohen, Yoshiya Tanaka, Xavier Mariette, Jeffrey R. Curtis, Kenneth Kwok, E. LEE, Peter Nash, Kevin Winthrop, Christina Charles‐Schoeman, Krishan Thirunavukkarasu, (unknown), (unknown), Richard J. Riese, J. Wollenhaupt	4
7	Impact of etanercept-methotrexate therapy on patient-reported outcomes in moderately active rheumatoid arthritis: Australian results from the induction period of preserve trial 2012 ·Internal Medicine Journal ·Peter Nash, (unknown), Paul Bird, Eustratios Bananis, (unknown), Annette Szumski, Heather Jones, (unknown), (unknown), Krishan Thirunavukkarasu	1
8	Combining etanercept with traditional agents in the treatment of psoriasis: a review of the clinical evidence 2010 ·Journal of the European Academy of Dermatology and Venereology ·(unknown), Christopher J Quirk, (unknown), Con Dolianitis, (unknown), Krishan Thirunavukkarasu, (unknown)	24
9	Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in australian patients: A cross-sectional, multicenter study 2010 ·Clinical Therapeutics ·(unknown), Sarah Norris, (unknown), (unknown), (unknown), Stephen Hall, Richard O. Day, Peter Nash, Krishan Thirunavukkarasu, James Robertson, (unknown)	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact